Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07183592
Recruiting Not applicable

Impact of Infusion Line Change Frequency on Infectious Complications Related to Central Venous Catheters in the ICU - A Randomized Controlled Trial

NCT07183592 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-05-12
Last updated
2026-05-13

Condition(s) studied

Intensive Care (ICU)Central Venous Catheter Related InfectionsCritical Care NursingCatheter-associated Bloodstream Infections (CLABSI)Nursing Workload

Investigational drug(s) / intervention(s)

7-day Infusion set replacement4-day infusion set replacement

7-day Infusion set replacement: 7-day infusion set replacement (Experimental arm) In this group, the infusion sets (the tubes and connectors used to deliver medications through the central venous catheter) will be changed once a week, every 7 days. During each replacement, all sets will be disconnected and replaced with new sterile ones.

4-day infusion set replacement: 4-day infusion set replacement (Active comparator arm) In this group, the infusion sets will be changed every 4 days, which reflects the most common international recommendation. The procedure is the same: all sets connected to the central venous catheter will be replaced with new sterile ones. This strategy represents the current standard of care and will serve as the comparison for the 7-day approach.

Study summary

In the intensive care unit, patients' care and secure drugs administration require a central venous catheter. These invasive devices can lead to complications, particularly infections. Most preventive recommendations focus on catheter insertion, line handling, and dressings. Few recommendations adress catheter dwell time, which is certainly the main source of infection. Part of the prevention strategy is the regular and systematic replacement of infusion sets , as they may become contaminated during use, mainly through the hands of healthcare professionals. Prolonged use increases the risk of infection. Infusion lines changes involve disconnecting the old sets, discarding infusion devices containing drug residues, and replacing them with new sterile devices.

Current international guidelines recommend replacing these sets every 4 days, and the Center for Disease Control and Prevention recommends not exceeding 7 days. Replacing these devices requires the time of qualified nurses, numerous sterile medical devices, and medications. In addition to the intended effect on infection prevention, the procedure has impacts on workload and costs.

The objective of the study is to demonstrate that changing infusion set every 7 days does not increase the rate of central venous catheters related infections compared with changing infusion set every 4 days.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria * Adult patient * Any ICU patient with a central venous catheter (inserted by venipuncture) in place for less than 72 hours and with an expected dwell time of at least 7 days * Patient affiliated with or covered by a social security system * Patient who has given verbal consent or written consent from a third party or in the event that the patient is unable to give consent. Exclusion Criteria * Patient with a documented bloodstream infection at the time of inclusion * Patient whose central venous catheter has been in place for more than 72 hours * Patient with suspected catheter-related infection * Patient whose study catheter was inserted using a guidewire exchange * Patient previously enrolled in the study during the same ICU stay * Patient whose condition, according to the clinician, does not allow safe placement of a central venous catheter, such as: * Allergy to catheter material * Confirmed deep vein thrombosis at the time of insertion * Inflammatory skin disorder at the insertion site * Patient admitted for extensive burns * Inadequate understanding of the French language * Pregnant, breastfeeding, or postpartum woman * Person deprived of liberty by judicial or administrative decision * Person receiving involuntary psychiatric care * Person under legal guardianship or other legal protection measure

Primary outcome measure(s)

Trial sites (27)

FacilityCityRegionStatus
La Réunion University Hospital Saint-Pierre La Réunion Not Yet Recruiting
Albi Hospital Albi France Not Yet Recruiting
Angers University Hospital Angers France Recruiting
Belfort Hospital Belfort France Not Yet Recruiting
Bourges Hospital Bourges France Not Yet Recruiting
Caen University Hospital Caen France Not Yet Recruiting
CH Carcassonne Carcassonne France Not Yet Recruiting
Chartres Hospital Chartres France Not Yet Recruiting
Cholet Hospital Cholet France Not Yet Recruiting
Colombes Hospital Colombes France Not Yet Recruiting
Corbeil-Essonnes Hospital Corbeil-Essonnes France Not Yet Recruiting
AP-HP - Henri Mondor Hospital Créteil France Not Yet Recruiting
Dijon University Hospital Dijon France Not Yet Recruiting
Garches Hospital Garches France Not Yet Recruiting
CH Le Mans Le Mans France Not Yet Recruiting
Le Puy en Velay Hospital Le Puy-en-Velay France Not Yet Recruiting
Macon Hospital Mâcon France Not Yet Recruiting
Nantes University Hospital Nantes France Not Yet Recruiting
Orleans University Hospital Orléans France Not Yet Recruiting
AP-HP - Tenon Hospital Paris France Not Yet Recruiting
AP-HP - Saint Louis Paris France Not Yet Recruiting
Pontoise Hospital Pontoise France Not Yet Recruiting
CHU Rennes - service MIR Rennes France Not Yet Recruiting
CHU Rennes - service Réa chir Rennes France Not Yet Recruiting
CH Saint-Nazaire Saint-Nazaire France Not Yet Recruiting
Strasbourg University Hospital Strasbourg France Not Yet Recruiting
CHU Tours Tours France Not Yet Recruiting

More University Hospital, Angers trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07183592 on ClinicalTrials.gov ↗ ← All trials in France